Small Cell Lung Cancer (SCLC)
Conditions
Brief summary
Confirmed OR (CR + PR), CR (Complete Response), PR (Partial Response)
Detailed description
serum concentrations of tarlatamab, DOR - Duration of confirmed response, DC -Disease control is defined as objective response or stable disease., Duration of DC, PFS-Progression-free survival, OR - Objective response is defined as best overall response of CR or PR., Overall survival (OS) -Overall survival is defined as the time from randomization to death due to any cause., OS rate at 6 months and 1 year from randomization, Incidence of treatment-emergent adverse events, Incidence of anti-tarlatamab antibody formation
Interventions
DRUGTarlatamab
DRUGSILTUXIMAB
Sponsors
Amgen Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Confirmed OR (CR + PR), CR (Complete Response), PR (Partial Response) | — |
Secondary
| Measure | Time frame |
|---|---|
| serum concentrations of tarlatamab, DOR - Duration of confirmed response, DC -Disease control is defined as objective response or stable disease., Duration of DC, PFS-Progression-free survival, OR - Objective response is defined as best overall response of CR or PR., Overall survival (OS) -Overall survival is defined as the time from randomization to death due to any cause., OS rate at 6 months and 1 year from randomization, Incidence of treatment-emergent adverse events, Incidence of anti-tarlatamab antibody formation | — |
Countries
Belgium, France, Germany, Greece, Italy, Spain
Outcome results
None listed